Get the Stockscreener App
2.78
2.11%
-0.06
After Hours:
2.88
0.10
+3.60%
Treace Medical Concepts Inc stock is traded at $2.78, with a volume of 334.40K.
It is down -2.11% in the last 24 hours and up +48.66% over the past month.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
See More
Previous Close:
$2.84
Open:
$2.84
24h Volume:
334.40K
Relative Volume:
0.41
Market Cap:
$180.35M
Revenue:
$212.69M
Net Income/Loss:
$-59.00M
P/E Ratio:
-2.9774
EPS:
-0.9337
Net Cash Flow:
$-29.49M
1W Performance:
+4.51%
1M Performance:
+48.66%
6M Performance:
-2.80%
1Y Performance:
-54.43%
1-Day Range:
$2.74
$2.8975
1-Week Range:
$2.53
$2.99
52-Week Range:
$1.17
$7.78
Treace Medical Concepts Inc Stock (TMCI) Company Profile
Name
Treace Medical Concepts Inc
Sector
Industry
Phone
(904) 373-5940
Address
100 PALMETTO PARK PLACE, PONTE VEDRA
Compare TMCI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMCI
Treace Medical Concepts Inc
|
2.78 | 184.24M | 212.69M | -59.00M | -29.49M | -0.9337 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Treace Medical Concepts Inc Stock (TMCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-04-25 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-31-24 | Initiated | Lake Street | Buy |
| Dec-17-24 | Resumed | JP Morgan | Neutral |
| May-16-24 | Downgrade | UBS | Buy → Neutral |
| May-08-24 | Downgrade | BTIG Research | Buy → Neutral |
| May-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-08-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-24 | Downgrade | Stifel | Buy → Hold |
| May-08-24 | Downgrade | Truist | Buy → Hold |
| Sep-29-23 | Initiated | UBS | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Apr-11-23 | Initiated | Stephens | Equal-Weight |
| May-12-22 | Initiated | BTIG Research | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-18-21 | Initiated | JP Morgan | Overweight |
| May-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-21 | Initiated | SVB Leerink | Outperform |
| May-18-21 | Initiated | Stifel | Buy |
View All
Treace Medical Concepts Inc Stock (TMCI) Latest News
Treace Medical Shareholders Back Directors, Pay and Auditor - TipRanks
Treace Medical Concepts shareholders elect directors and approve key proposals - Investing.com Australia
Treace Medical Concepts, Inc. 8-K SEC Filing Details and Company Information (May 19, 2026) - Minichart
Treace Medical (TMCI) shareholders elect directors and ratify auditor at 2026 meeting - Stock Titan
TMCI SEC FilingsTreace Medical Concepts, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Treace Medical Concepts (TMCI) director receives 30,000 RSU equity award - Stock Titan
Treace Medical (TMCI) director receives 30,000 RSU equity award and updates holdings - Stock Titan
Armistice Capital (TMCI) discloses 6.36M shares, 9.85% stake - Stock Titan
Treace Medical Concepts Q1 earnings call highlights - MSN
Treace Medical Concepts CEO John Treace buys $375,505 in shares By Investing.com - Investing.com Australia
Treace Medical Concepts CEO John Treace buys $375,505 in shares - Investing.com India
Treace Medical Concepts Insider Bought Shares Worth $375,505, According to a Recent SEC Filing - Moomoo
TMCI (TMCI) CEO John Treace purchases over 150,000 company shares in open market - Stock Titan
Bank of America (TMCI) reports 3.53M shares, 5.5% ownership - Stock Titan
Treace Medical Concepts, Inc. Shareholders Are Encouraged - GlobeNewswire
Treace Medical Concepts (TMCI) Price Target Decreased by 35.65% to 5.58 - MSN
Treace Medical Concepts Q1 Earnings Call Highlights - MarketBeat
Treace Medical Concepts (TMCI) Q4 Loss Narrowing To US$0.15 EPS Tests Bearish Narratives - Sahm
Treace Medical Concepts: Q1 Earnings Snapshot - theheraldreview.com
Treace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings Results - MarketBeat
Treace Hikes on Q1 Numbers - Baystreet.ca
Treace Medical Concepts, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Treace Medical Concepts beats Q1 2026 forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Treace Medical Concepts beats Q1 2026 forecasts - Investing.com
Treace Medical Concepts Backs 2026 Rev $202M-$212M >TMCI - Moomoo
Treace Medical Concepts Inc (NASDAQ:TMCI) Jumps 9% Pre-Market After Q1 Earnings Beat Despite Revenue Decline - ChartMill
Treace Medical Concepts, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Treace Medical Concepts Reports First Quarter 2026 Financial Results - The Manila Times
Treace Medical Concepts reports Q1 2026 revenue $47.2M, net loss $18.0M, reaffirming 2026 guidance - TradingView
[10-Q] TREACE MEDICAL CONCEPTS, INC. Quarterly Earnings Report - Stock Titan
Bunion surgery device maker posts 10% sales drop, keeps 2026 target - Stock Titan
Treace Medical (NASDAQ: TMCI) Q1 2026 sales fall 10% as losses widen - Stock Titan
Treace Medical Concepts, Inc. Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Treace Medical Concepts, Inc. (TMCI) Investor Outlook: Exploring A Potential 121% Upside - DirectorsTalk Interviews
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
How The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst Expectations - Yahoo Finance
Treace Medical Concepts (TMCI) to Release Earnings on Friday - MarketBeat
Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08 - MSN
Weber Capital Management LLC ADV Invests $1.45 Million in Treace Medical Concepts, Inc. $TMCI - MarketBeat
Treace Medical Concepts (NASDAQ:TMCI) Upgraded to Sell at Wall Street Zen - MarketBeat
Zimmer Biomet sued for violating Treace Medical patents related to bunion treatment - MSN
Treace to Report First Quarter 2026 Financial Results on May 8, 2026 - The Manila Times
Treace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference Call - Quiver Quantitative
Treace Medical Concepts Inc Stock (TMCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):